1. Date of download: 6/24/2016 From: Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis Ann Intern Med. 2013;159(4):262-274. doi:10.7326/0003-4819-159-4-201308200-00007 Summary of evidence search and selection. EMA = European Medicines Agency; FDA = U.S. Food and Drug Administration. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

2. Date of download: 6/24/2016 From: Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis Ann Intern Med. 2013;159(4):262-274. doi:10.7326/0003-4819-159-4-201308200-00007 Weighted mean difference in change in hemoglobin A 1c level from baseline: SGLT2 inhibitors versus placebo. Results are from IV random-effects meta-analysis. IV = inverse variance; SGLT2 = sodium–glucose cotransporter 2. * Reference 48 includes 2 randomized trials of dapagliflozin at doses of 5 mg (study 1) and 10 mg (study 2). Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

3. Date of download: 6/24/2016 From: Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis Ann Intern Med. 2013;159(4):262-274. doi:10.7326/0003-4819-159-4-201308200-00007 Weighted mean difference in change in hemoglobin A 1c level from baseline: SGLT2 inhibitors versus other antidiabetic drugs. Results are from IV random-effects meta-analysis. IV = inverse variance; SGLT2 = sodium–glucose cotransporter 2. * Reference 48 includes 2 randomized trials of dapagliflozin at doses of 5 mg (study 1) and 10 mg (study 2). Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians